IBA and Penn Medicine Create Noventra Oncology Alliance in Proton Therapy
IBA and Penn Medicine announced on September 28, 2026 the creation of Noventra Oncology Alliance, a joint venture dedicated to supporting healthcare facilities in developing proton therapy and radiation oncology programs. The entity combines the clinical expertise of the American institution with the technologies of the Belgian group.
A Joint Venture Focused on Proton Therapy Programs
IBA (Ion Beam Applications), headquartered in Louvain-la-Neuve, and Penn Medicine, based in Philadelphia, announced on September 28, 2026 the creation of Noventra Oncology Alliance.
This joint venture is designed to support healthcare facilities in the development, deployment and optimization of their proton therapy and radiation oncology programs.
The entity will offer an integrated service offering covering strategic and financial planning, preparation and implementation of clinical programs as well as their long-term operational performance.
A Consulting Offering Covering All Stages of Projects
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The joint venture will offer integrated consulting and support services for each stage of projects, with the objective of helping healthcare facilities develop and sustain their proton therapy programs.
According to the press release, the success of such a program is not limited to equipment acquisition. Healthcare facilities must also address issues related to strategic planning, capital investment, healthcare reimbursement, skills development, clinical preparation, operational performance, research infrastructure and long-term program growth.
Comments from the Two Partners
James Metz, Chair of Radiation Oncology at the Perelman School of Medicine at the University of Pennsylvania, stated that by combining Penn Medicine's decades of experience in building and managing one of the world's most recognized proton therapy programs with IBA's expertise in technology and implementation, Noventra Oncology Alliance creates a unique initiative enabling healthcare facilities to deliver excellent care.
Henri de Romrée, Deputy CEO of IBA, stated that Noventra Oncology Alliance helps healthcare facilities reduce clinical, operational and financial risks associated with developing radiation oncology programs, while playing a key role in strengthening the value of this technology in cancer treatment and accelerating its adoption on a larger scale.
Additional information will be presented at the ASTRO 2026 annual congress in Boston.
SectorDispositifs médicaux et optique›Dispositifs médicaux
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 323,7 millions d'euros
Quarterly revenue: 323,7 millions d'euros
EBITDA: 21,8 millions d'euros
EBITDA margin: 8,2 %
Net income: 9,3 millions d'euros
81 millions d'euros
Guidance from the release
Prévisions d'EBIT ajusté pour l'exercice 2026 confirmées, reflétant la confiance du Groupe dans ses perspectives pour l'ensemble de l'année.
Risks mentioned
Surcapacité persistante sur le marché d'Industrial Solutions malgré un pipeline actif.
Retards temporaires de facturation liés à la migration ERP qui ont impacté la position financière nette.
Dosimetry reste sous pression malgré les mesures de réduction des coûts.
Opportunities identified
Forte dynamique commerciale en Proton Therapy avec cinq salles vendues et cinq prises de commandes de plus de €148 millions au S1.
PanTera a obtenu la qualification de fournisseur c-GMP d'actinium-225 et extension de collaboration avec TerraPower Isotopes pour tripler la capacité de production en Belgique.
Amélioration continue de la rentabilité : marge brute passée de 29,5% à 33,7% et EBITDA ajusté en croissance de 63%.
Outlook / guidance
Management commentary: Prévisions d'EBIT ajusté pour l'exercice 2026 confirmées à au moins € 32 millions
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
